<b>Methods:</b> Clinical data on children with RUNX1::RUNX1T1-positive AML with KIT mutations who received avapritinib at the Department of Pediatrics, Peking University People's Hospital, from September 2022 to June 2025 were collected. This evidence concerns the gene KIT and acute myeloid leukemia.